EUDA Health Signs MoU With GO POSB Organoids And Shenzhen Innovation Immunotechnology To Collaborate On Therapies Derived From Induced Pluripotent Stem Cells
The MOU details the parties intentions to collaborate on the development, manufacturing and commercialization of a first of its kind next generation of off-the-shelf oncology cell therapies for cancer treatment
EUDA Health agreed to work with two other companies to create new cancer medicines using special cells that can become many different types of cells. This shows EUDA is trying to build something new and important, but it's just a starting plan—not a finished product yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.